ERBB2 and breast carcinoma: This systematic review and meta-analysis aimed to assess whether adding pertuzumab to neoadjuvant chemotherapy and trastuzumab can improve the pathologic complete response (pCR) rates in early-stage HER2-positive breast cancer patients.